

Amount in (Crores)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments		Details of the loans, inter-corporate deposits, advances or investments							
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Receivable or indebtedness + (loan)/ issuance of debt/ any	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
Add		Delete																						
1	Alembic Pharmaceuticals Ltd.		Alembic Global Holding SA		Wholly owned Subsidiary	Loan		0.00	No remarks			0.00	10.26	10.65				Loan	7.00%	3 Years	Unsecured	Business Purpose	Amount Change due to Exchange rate difference	
2	Alembic Pharmaceuticals Ltd.		Alembic Global Holding SA		Wholly owned Subsidiary	Loan		0.00	No remarks			0.00	42.73	44.39				Loan	7.70%	3 Years	Unsecured	Business Purpose	Amount Change due to Exchange rate difference	
3	Alembic Pharmaceuticals Ltd.		Alembic Global Holding SA		Wholly owned Subsidiary	Loan		0.00	No remarks			0.00	8.55	8.88				Loan	6.79%	3 Years	Unsecured	Business Purpose	Amount Change due to Exchange rate difference	
4	Alembic Pharmaceuticals Ltd.		Alembic Global Holding SA		Wholly owned Subsidiary	Interest received		2.56	No remarks			2.56	4.77	2.60									On account of interest received and Amount adjusted due to Exchange rate difference	
5	Alembic Pharmaceuticals Ltd.		Alembic Global Holding SA		Wholly owned Subsidiary	Sale of goods or services		349.69	No remarks			349.69	121.19	159.25										
6	Alembic Pharmaceuticals Ltd.		Alembic Global Holding SA		Wholly owned Subsidiary	Investment		0.00	No remarks			0.00	30.31	30.31				Investment	0.00%	NA	Unsecured	Business Purpose	Investment in Equity	
7	Alembic Pharmaceuticals Ltd.		Alembic Global Holding SA		Wholly owned Subsidiary	Loan		0.00	No remarks			10.33	0.00	10.65				Loan	6.57%	3 Years	Unsecured	Business Purpose	Amount adjusted due to Exchange rate difference	
8	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Any other transaction	Service Received	17.21	No remarks			17.21	6.16	3.30										
9	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Any other transaction	Reimbursement Paid	3.27	No remarks			3.27	0.00	0.00										
10	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Any other transaction	Rent Paid	5.95	No remarks			5.95	0.00	0.00										
11	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Sale of goods or services		0.14	No remarks			0.14	0.00	0.00										
12	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Any other transaction	Deposit Given	0.00	No remarks			0.00	3.30	3.30										
13	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Purchase of goods or services		4.48	No remarks			4.48	0.00	0.00										
14	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals SPA Chile		Wholly owned Subsidiary	Any other transaction	Reimbursement of expenses	2.60	No remarks			2.60	0.00	0.00										
15	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals SPA Chile		Wholly owned Subsidiary	Any other transaction	Corporate Guarantee given	0.00	No remarks			0.00	85.47	88.79									Amount Change due to Exchange rate difference	
16	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals SPA Chile		Wholly owned Subsidiary	Investment		0.00	No remarks			0.00	2.40	2.40				Investment	0.00%	NA	Unsecured	Business Purpose	Investment in Equity	
17	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals SPA Chile		Wholly owned Subsidiary	Loan		0.00	No remarks			0.00	17.09	17.76				Loan	7.00%	3 Years	Unsecured	Business Purpose	Amount Change due to Exchange rate difference	
18	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals SPA Chile		Wholly owned Subsidiary	Sale of goods or services		33.05	No remarks			33.05	41.05	65.40										
19	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals SPA Chile		Wholly owned Subsidiary	Interest received		0.61	No remarks			0.61	0.72	0.61										
20	Alembic Pharmaceuticals Ltd.		Bhailal Amin General Hospital		Promoter Group	Purchase of goods or services		2.72	No remarks			2.72	1.02	0.85										
21	Alembic Pharmaceuticals Ltd.		Alembic City Ltd.		Promoter Group	Any other transaction	Rent Paid	0.05	No remarks			0.05	0.00	0.00										
22	Alembic Pharmaceuticals Ltd.		Alembic City Ltd.		Promoter Group	Any other transaction	Deposit Given	0.00	No remarks			0.00	0.03	0.03										
23	Alembic Pharmaceuticals Ltd.		Alembic City Ltd.		Promoter Group	Any other transaction	Reimbursement Paid	0.08	No remarks			0.08	0.00	0.00										
24	Alembic Pharmaceuticals Ltd.		Alembic CSR Foundation		Other Related Parties	Any other transaction	CSR Contribution	5.58	No remarks			5.58	0.00	0.00										
25	Alembic Global Holding SA		ALEMBIC PHARMACEUTICALS SA de CV		Fellow Subsidiary	Loan		0.88	No remarks			0.88	0.88	0.00				Loan	6.00%	1 Year	Unsecured	Business Purpose	Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ99992 as PAN of ALEMBIC PHARMACEUTICALS SA de CV	
26	Alembic Global Holding SA		ALEMBIC PHARMACEUTICALS SA de CV		Fellow Subsidiary	Interest received		0.06	No remarks			0.06	0.06	0.00										
27	Alembic Global Holding SA		ALEMBIC PHARMACEUTICALS SA de CV		Fellow Subsidiary	Investment		0.00	No remarks			0.00	0.00	0.00				Investment	0.00%	NA	Unsecured	Business Purpose	Investment in Equity USD 33.24 invested.	
28	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Limited Provident Fund		Other Related Parties	Any other transaction	Post Retirement benefits	58.56	No remarks			58.56	0.00	0.00										
29	Alembic Pharmaceuticals Ltd.		Shreno Ltd.		Promoter Group	Purchase of goods or services		0.14	No remarks			0.14	0.03	0.03										
30	Alembic Pharmaceuticals Ltd.		Shreno Ltd.		Promoter Group	Any other transaction	Rent Paid	0.33	No remarks			0.33	0.00	0.00										
31	Alembic Pharmaceuticals Ltd.		Shreno Ltd.		Promoter Group	Any other transaction	Deposit Given	0.00	No remarks			0.00	0.08	0.08										
32	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Inc.		Wholly owned Subsidiary	Any other transaction	Corporate Guarantee given	292.89	No remarks			292.89	85.47	381.80									Amount adjusted due to Exchange rate difference	
33	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Inc.		Wholly owned Subsidiary	Investment		0.00	No remarks			0.00	122.36	122.36				Investment	0.00%	NA	Unsecured	Business Purpose	Investment in Equity	
34	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Inc.		Wholly owned Subsidiary	Sale of goods or services		622.79	No remarks			622.79	943.10	772.89									Amount adjusted due to Exchange rate difference	
35	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Inc.		Wholly owned Subsidiary	Any other transaction	Reimbursement Paid	5.07	No remarks			5.07	0.00	0.00										
36	Alembic Pharmaceuticals Ltd.		Shreno Publications Ltd.		Promoter Group	Purchase of goods or services		31.47	No remarks			31.47	4.87	5.50										
37	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Europe Ltd.		Step down Subsidiary	Any other transaction	Reimbursement Paid	0.00	No remarks			0.00	2.15	0.00										
38	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Australia Pty Ltd.		Step down Subsidiary	Any other transaction	Reimbursement Paid	0.00	No remarks			0.00	1.92	0.00										
39	Alembic Pharmaceuticals Ltd.		Paushak Ltd.		Promoter Group	Purchase of goods or services		3.81	No remarks			3.81	0.24	0.70										
40	Alembic Pharmaceuticals Ltd.		Paushak Ltd.		Promoter Group	Any other transaction	Reimbursement Received	0.20	No remarks			0.20	0.00	0.00										
41	Alembic Pharmaceuticals Ltd.		Rakshak Services Pvt. Ltd.		Other Related Parties	Purchase of goods or services		0.81	No remarks			0.81	0.17	0.00										
42	Alembic Pharmaceuticals Ltd.		Shreno Engineering Ltd.		Promoter Group	Purchase of fixed assets		9.81	No remarks			9.81	1.42	0.00										
43	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Limited Gratuity Fund		Other Related Parties	Any other transaction	Post Retirement benefits	10.00	No remarks			10.00	0.00	0.00										
44	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Limited Super Annuation Scheme		Other Related Parties	Any other transaction	Post Retirement benefits	1.14	No remarks			1.14	0.00	0.00										
45	Alembic Pharmaceuticals Ltd.		Rhizen Pharmaceuticals AG		Associate of Subsidiary	Any other transaction	Reimbursement Paid	0.00	No remarks			0.00	0.99	1.03									Amount Change due to Exchange rate difference	
46	Alembic Pharmaceuticals Ltd.		Fenix Research Labs Private Limited		Associate	Investment		0.00	No remarks			0.00	3.00	3.00				Investment	0.00%	NA	Unsecured	Business Purpose	Investment in Equity	
47	Alembic Pharmaceuticals Ltd.		Fenix Research Labs Private Limited		Associate	Sale of goods or services		0.00	No remarks			0.00	0.04	0.04										
48	Alembic Global Holding SA		Rhizen Pharmaceuticals AG		Associate	Investment		0.00	No remarks			0.00	17.01	17.01				Investment	0.00%	NA	Unsecured	Business Purpose	Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ99992 as PAN of Rhizen Pharmaceuticals AG	
49	Alembic Global Holding SA		TicTwo Therapeutics Inc.		Subsidiary	Loan		0.00	No remarks			17.75	53.42	73.25				Loan	9.00%	3 years	Unsecured	Business Purpose	Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ99992 as PAN of TicTwo Therapeutics Inc. Amount	
50	Alembic Global Holding SA		TicTwo Therapeutics Inc.		Subsidiary	Investment		0.00	No remarks			0.00	0.01	0.01				Investment	0.00%	NA	Unsecured	Business Purpose	Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ99992 as PAN of TicTwo Therapeutics Inc. Amount	
51	Alembic Global Holding SA		TicTwo Therapeutics Inc.		Subsidiary	Interest received		0.00	No remarks			2.76	3.87	6.78										
52	Alembic Pharmaceuticals Ltd.		ALEMBIC PHARMACEUTICALS SA de CV		Subsidiary	Loan		1.71	No remarks			1.71	0.00	1.78				Loan	6.61%	3 years	Unsecured	Business Purpose	Amount Change due to Exchange rate difference	

53	Alembic Pharmaceuticals Ltd.	ALEMBIC PHARMACEUTICALS SA de CV	Subsidiary	Interest received		0.04	No remarks			0.04	0.00	0.05									Amount adjusted due to Exchange rate difference
54	Alembic Pharmaceutcals Ltd.	ALEMBIC PHARMACEUTICALS SA de CV	Subsidiary	Investment		0.03	No remarks			0.03	0.00	0.03				Investment	0.00%	NA	Unsecured	Business Purpose	Investment in Equity
55	Alembic Pharmaceuticals Ltd.	Chirayu Ramanbhai Amin	Key Managerial Personnel	Remuneration		7.03	No remarks			7.03	5.00	2.50									
56	Alembic Pharmaceuticals Ltd.	Pranav Chirayu Amin	Key Managerial Personnel	Remuneration		9.60	No remarks			9.60	5.00	5.00									
57	Alembic Pharmaceuticals Ltd.	Shashank Chirayu Amin	Key Managerial Personnel	Remuneration		9.60	No remarks			9.60	5.00	5.00									
58	Alembic Global Holding SA	Udit Chirayu Amin	Relative to Key Managerial Person	Remuneration		4.32	No remarks			4.32	0.00	0.00									Since Alembic Global Holdings SA (AGHSA) is an Offshore Entity and does not have PAN, we have mentioned the
59	Alembic Global Holding SA	Alembic Lifescience Limited	Subsidiary	Loan		0.00	No remarks			2.31	0.00	2.31				Loan	6.32%	3 years	Unsecured	Business Purpose	Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Lifescience Limited.
60	Alembic Global Holding SA	Alembic Lifescience Limited	Subsidiary	Interest received		0.00	No remarks			0.04	0.00	0.04									Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Lifescience Limited.
61	Alembic Global Holding SA	Alembic Lifescience Limited	Subsidiary	Investment		0.00	No remarks			0.00	0.00	0.00				Investment	0.00%	NA	Unsecured	Business Purpose	Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Lifescience Limited.
Total value of transaction during the reporting period										1531.47											

Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.

2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.

3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.

4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31.

Companies with financial years ending in other months, the six months period shall apply accordingly.

5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type.

However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.

6. In case of a multi-year related party transaction:

a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".

b. The value of the related party transaction ratified by the audit committee shall be disclosed in the column "Value of the related party transaction ratified by the audit committee".

c. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".

7. "Cost" refers to the cost of borrowed funds for the listed entity. 8. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.